The present invention relates to a method for the treatment, amelioration orelimination of acute lymphoblastic leukemia (ALL), the method comprising theadministration of a pharmaceutical composition comprising a CD19xCD3bispecificsingle chain antibody construct, also known as MT103/Blinatumomab, to an adultpatient.